BARICIPAC Trademark

Trademark Overview

On Wednesday, September 21, 2022, a trademark application was filed for BARICIPAC with the United States Patent and Trademark Office. The USPTO has given the BARICIPAC trademark a serial number of 79369234. The federal status of this trademark filing is REGISTERED as of Tuesday, June 18, 2024. This trademark is owned by Pacific Pharmaceuticals Pte Ltd.. The BARICIPAC trademark is filed in the Pharmaceutical Products category with the following description:

Mineral dietary supplements for humans; Pharmaceutical drugs comprising Janus Kinase (JAK) inhibitors for the treatment of severe Coronavirus infection, alopecia areata and severe rheumatoid arthritis
baricipac

General Information

Serial Number79369234
Word MarkBARICIPAC
Filing DateWednesday, September 21, 2022
Status700 - REGISTERED
Status DateTuesday, June 18, 2024
Registration Number7416516
Registration DateTuesday, June 18, 2024
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, April 2, 2024

Trademark Statements

Goods and ServicesMineral dietary supplements for humans; Pharmaceutical drugs comprising Janus Kinase (JAK) inhibitors for the treatment of severe Coronavirus infection, alopecia areata and severe rheumatoid arthritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 12, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePacific Pharmaceuticals Pte Ltd.
Party Type30 - Original Registrant
Legal Entity Type13 - Limited Partnership
AddressSG
Party NamePacific Pharmaceuticals Pte Ltd.
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressSG
Party NamePacific Pharmaceuticals Pte Ltd.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressSG

Trademark Events

Event DateEvent Description
Friday, May 12, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 11, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, May 16, 2023APPLICATION FILING RECEIPT MAILED
Monday, July 3, 2023ASSIGNED TO EXAMINER
Friday, July 7, 2023NON-FINAL ACTION WRITTEN
Saturday, July 8, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, August 14, 2023REFUSAL PROCESSED BY MPU
Monday, August 14, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, September 5, 2023REFUSAL PROCESSED BY IB
Wednesday, February 7, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 7, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 8, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 27, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, February 27, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, February 27, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, February 27, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, March 13, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 27, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 27, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, April 2, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 2, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 16, 2024NOTIFICATION PROCESSED BY IB
Thursday, February 29, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 18, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Wednesday, September 18, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 18, 2024REGISTERED-PRINCIPAL REGISTER

Related Keywords

baricipac severe coronavirus treatment infection alopecia arthritis rheumatoid areata inhibitors kinase